Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, Sjoberg I, Ryd W, Silins I, Dillner J, Swedescreen Study Group. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. American Journal of Obstetrics and Gynecology 2005; 193: 650-657.
Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. Journal of Medical Virology 2002; 66: 535-541.
Gustafsson L, Sparen P, Gustafsson M, Wilander E, Bergstrom R, Adami HO. Efficiency of organized and opportunistic cytological screening for cancer in situ of the cervix. British Journal of Cancer 1995; 72: 498-505.
Hakama M, Hristova L. Effect of screening in the Nordic cancer control up to the year 2017. Acta Oncologia 1997; 36: 119-128.
van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-) effectiveness. British Journal of Cancer 1997; 76: 651-657.